Intellia Therapeutics (NTLA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Chairperson welcomed attendees and introduced board members and executive team, including key officers and the independent auditor.
Meeting agenda included formal business as set forth in the Notice of Annual Meeting and Proxy Statement.
Board and executive committee updates
Board members and executive officers present were introduced, including roles such as CEO, CFO, CTO, and General Counsel.
Inspector of Election and independent auditor were identified and their roles explained.
Shareholder proposals
Three proposals were presented: election of three Class I directors, ratification of the independent auditor, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Intellia Therapeutics
- Single-dose gene editing therapy delivers robust, durable HAE control with U.S. launch targeted for 2027.NTLA
Jefferies Global Healthcare Conference 20263 Jun 2026 - First phase III in vivo CRISPR trial completed, with strong HAE results and global TTR progress.NTLA
RBC Capital Markets Global Healthcare Conference 202620 May 2026 - Phase III data show superior efficacy for lonvo-z, with commercial launch targeted for next year.NTLA
Bank of America Global Healthcare Conference 202615 May 2026 - Positive Phase 3 HAE data, resumed ATTR trials, and cash runway extend operations into 2028.NTLA
Q1 202611 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.NTLA
Proxy filing30 Apr 2026 - Proxy covers director elections, auditor ratification, pay, and strong governance and ESG focus.NTLA
Proxy filing30 Apr 2026 - Lonvo-z achieved 87% attack reduction and 62% attack-free rates in Phase 3 HAELO trial.NTLA
Study result28 Apr 2026 - Mid-year data from a pivotal HAE study could enable a first-in-class gene editing launch next year.NTLA
Leerink Global Healthcare Conference 20269 Mar 2026 - lonvo-z Phase III results expected mid-2026, with U.S. launch and high-margin revenue targeted for 2027.NTLA
TD Cowen 46th Annual Health Care Conference3 Mar 2026